SEC Company Response from Transcode Therapeutics, (RNAZ) — May 15, 2026
Transcode Therapeutics, Inc.
Date: May 15, 2026 · CIK: 0001829635 · Accession: 0001104659-26-062704
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-295473
Letter
Re: TransCode Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-295473
May 15, 2026
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, the undersigned registrant, TransCode Therapeutics, Inc., a Delaware corporation (the " Registrant "), hereby requests that the above-referenced Registration Statement on Form S-3 (the " Registration Statement ") be declared effective at 4:00 p.m., Eastern Time, on May 19, 2026 or as soon as practicable thereafter. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Orrick, Herrington & Sutcliffe LLP, by calling Niki Fang at (415) 773-5540.
The Registrant hereby authorizes Niki Fang of Orrick, Herrington & Sutcliffe LLP to orally modify or withdraw this request for acceleration.
Thank you for your assistance in this matter.
Kind regards,
TRANSCODE THERAPUETICS, INC.
By: /s/ Thomas A. Fitzgerald
Name: Thomas A. Fitzgerald
Title: Chief Financial Officer
cc: Niki Fang, Orrick, Herrington & Sutcliffe LLP
Show Raw Text
CORRESP 1 filename1.htm May 15, 2026 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: TransCode Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-295473 Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, the undersigned registrant, TransCode Therapeutics, Inc., a Delaware corporation (the " Registrant "), hereby requests that the above-referenced Registration Statement on Form S-3 (the " Registration Statement ") be declared effective at 4:00 p.m., Eastern Time, on May 19, 2026 or as soon as practicable thereafter. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Orrick, Herrington & Sutcliffe LLP, by calling Niki Fang at (415) 773-5540. The Registrant hereby authorizes Niki Fang of Orrick, Herrington & Sutcliffe LLP to orally modify or withdraw this request for acceleration. Thank you for your assistance in this matter. Kind regards, TRANSCODE THERAPUETICS, INC. By: /s/ Thomas A. Fitzgerald Name: Thomas A. Fitzgerald Title: Chief Financial Officer cc: Niki Fang, Orrick, Herrington & Sutcliffe LLP